CAR-T Cell Therapy

Re-engineering a patient's own T-cells into living cancer hunters.

CAR-T is a 'living drug'. A patient's own T-cells are drawn off, then genetically fitted with a chimeric antigen receptor — a synthetic sensor that recognises a marker on cancer cells (CD19 in lymphoma, BCMA in myeloma). The cells are multiplied into the millions and infused back, where they hunt, kill, and persist.

In blood cancers the results have been transformative, including lasting remissions. The frontiers now are solid tumours (much harder to penetrate) and, strikingly, autoimmune disease — resetting a misfiring immune system. That's the same tolerance problem Polish cell-therapy players are chasing from the Treg side.

How it works in depth

CAR-T (chimeric antigen receptor T-cell) therapy is a form of adoptive cell therapy. Clinicians collect a patient's own T-cells via leukapheresis, ship them to a manufacturing facility, and use a viral vector (typically lentivirus or retrovirus) to insert a gene encoding a synthetic receptor. That chimeric receptor fuses an antibody-derived domain that recognizes a tumor antigen to internal T-cell signaling domains (CD3-zeta plus a costimulatory domain such as 4-1BB or CD28). The edited cells are expanded into the hundreds of millions, the patient receives lymphodepleting chemotherapy, and the cells are reinfused, where they proliferate as "living drugs" that recognize and kill antigen-bearing cells.

Approved autologous products target either CD19 (B-cell leukemias and lymphomas) or BCMA (multiple myeloma). The signature toxicities are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), managed with tocilizumab and corticosteroids.

Where the field is in 2025-2026

Six autologous products are approved in the US: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti. In January 2024 the FDA required a class-wide boxed warning for secondary T-cell malignancies after reports of T-cell cancers following treatment; the agency reportedly identified 22 such cases as of late 2023, and lifelong monitoring is advised. In December 2025, FDA leaders outlined in JAMA a shift toward randomized controlled trials as the preferred standard for future CAR-T approvals. Carvykti and Breyanzi have both moved into earlier (second-line) settings in myeloma and lymphoma respectively. A major frontier is in vivo CAR-T, engineering T-cells inside the body via targeted lipid nanoparticles, and expansion into autoimmune disease (notably refractory lupus), where CD19 CAR-T can deeply deplete B-cells and reportedly reset immune tolerance.

Leading programs & players

Key commercial assets include Carvykti (Johnson & Johnson / Legend Biotech, ciltacabtagene autoleucel), Yescarta and Tecartus (Gilead/Kite), Breyanzi and Abecma (Bristol Myers Squibb), and Kymriah (Novartis). In December 2025 Breyanzi became the first CAR-T approved in the US for marginal zone lymphoma. The in vivo and autoimmune wave has drawn large deals: AstraZeneca's roughly $425 million upfront acquisition of EsoBiotec in March 2025, and Capstan Therapeutics dosing its first subjects with in vivo candidate CPTX2309 in 2025. Allogeneic ("off-the-shelf") efforts continue at companies like Allogene and CRISPR Therapeutics. Analysts project the CAR-T market growing into the tens of billions of dollars over the next decade, with debate centered on cost, access, manufacturing speed, durability, and pushing into solid tumors.

FAQ

What cancers does CAR-T treat?

Approved CAR-T therapies treat blood cancers: B-cell acute lymphoblastic leukemia, large B-cell and other non-Hodgkin lymphomas, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and multiple myeloma. Solid-tumor and autoimmune uses are still experimental.

How much does CAR-T cell therapy cost?

The list price of approved CAR-T products is generally around $400,000 to $500,000 for the cell product alone, before hospitalization and supportive care, making affordability and access a central debate in the field.

Is CAR-T therapy a permanent cure?

For some patients CAR-T produces durable, years-long remissions, but it is not guaranteed to be curative; many patients relapse, often through antigen loss. Outcomes vary widely by disease and individual.

What is in vivo CAR-T therapy?

In vivo CAR-T engineers a patient's T-cells directly inside the body, typically using targeted lipid nanoparticles, instead of extracting, modifying, and re-growing cells in a lab. As of 2025 it is in early clinical trials and aims to cut cost and complexity.

Companies working on CAR-T Cell Therapy

Explore the interactive landscapes →